FEDERAL SIGNALS · BEHAVIORAL HEALTH · HUMAN AGENCY

The Human Layer Around Behavioral Health

What 988 expansion and FDA’s 2026 psychedelic initiatives reveal about continuity, supportive environments, human agency, and evidence.

The signal is not only the funding. It is the system around the person.

Two federal developments deserve attention from anyone designing systems around behavioral health.

First, on September 8, 2026, the U.S. Department of Health and Human Services announced $383.4 million in behavioral-health grants, including $252 million for 988, suicide prevention, and mobile crisis services. The awards emphasize capacity, crisis response, community-based services, and connections across the behavioral-health system.

Second, the U.S. Food and Drug Administration finalized 2026 guidance for clinical investigations involving psychedelic drugs and scheduled a public hearing concerning potential future therapeutic use in supervised and supportive settings. The hearing asks about provider training, patient safety, access, informed consent, set and setting, post-administration follow-up, crisis coordination, privacy, interoperability, and longitudinal data.

These developments do not validate Cognitive State Systems™, SATA-CODA™, or any other specific product. They do, however, reinforce a broader design question.

When care becomes a complex system, what happens to the human being moving through it?

That question is the Human Layer.

The signal is bigger than the funding

The September 8 HHS announcement is significant because of its size, but the more important signal is structural.

The federal government is investing not only in treatment capacity, but in connective functions around behavioral health: 988 response, mobile crisis, prevention, recovery support, community-based systems of care, and the ability to connect people to appropriate next resources.

That matters because a person does not experience a behavioral-health system as an organizational chart. Real systems also depend on whether people can understand where they are, reach the right next resource, move between services, maintain continuity, and remain active participants rather than passive objects of a fragmented process.

SAMHSA’s 2026 work on 988 crisis-center follow-up makes that point especially visible. Systematic follow-up, coordination, linkage to ongoing support, and continuity after an initial contact are not merely communication tasks. They are design problems.

Continuity is part of system design.

Answering the call is only the beginning

A crisis line can be an essential front door. But a front door is not the entire building.

After the immediate interaction come other questions:

  • Does the person understand what happens next?
  • Is the next step clear?
  • Can the system preserve continuity without overwhelming the person?
  • Are responsibilities visible across organizations?
  • Is information shared appropriately and with clear permission boundaries?
  • Is there a reliable path back to a human when circumstances change?
  • Does technology assist the experience without becoming the authority over it?

These are not substitutes for clinical practice. They are questions about the experience surrounding clinical and community systems.

Clinical decisions, diagnosis, treatment, crisis intervention, and therapeutic responsibility belong with qualified providers and accountable care organizations.

The Human Layer concerns the design around those functions: orientation, consent, continuity, environment, accessibility, reflection, participant control, data boundaries, and human escalation.

FDA is asking what surrounds the intervention

FDA’s 2026 work on psychedelic drug development makes the surrounding system unusually visible.

In July, FDA finalized guidance for sponsors conducting clinical investigations of psychedelic drugs. The agency also scheduled a September public hearing on potential future therapeutic use in supervised and supportive settings.

The hearing is not a referendum on any particular product. FDA is explicitly seeking input on the infrastructure and safeguards that could surround future therapeutic use.

Provider training Patient education Informed consent Set and setting Monitoring Post-session follow-up Crisis coordination Access models Data quality Privacy Interoperability Longitudinal follow-up

Those questions are important well beyond psychedelics.

They reveal a general truth about consequential human systems: the intervention cannot be separated from the conditions in which a person encounters it.

Environment matters. Communication matters. Consent matters. Transitions matter. Follow-up matters. Data governance matters. Human accountability matters.

The Human Layer is a design problem

At Cognitive State Systems™, we use the phrase Human Layer to describe the part of an intelligent or complex system that must remain deliberately designed around the person.

It is not a claim that technology can replace care. It is the opposite.

The more capable the system becomes, the more explicit its human boundaries should become.

01

Orientation

Can a person understand where they are, what is happening, what the system can and cannot do, and what comes next?

02

Consent and agency

Can the person make an informed choice, pause, exit, ask for a human, or change direction?

03

Continuity

What happens between interactions, providers, locations, or phases of an experience?

04

Environment

What does the physical, digital, social, and sensory environment communicate to the person?

05

Data and AI boundaries

What is collected, inferred, automated, shared, and left to accountable human judgment?

06

Escalation and accountability

When should technology stop and a qualified human take over?

What these federal developments do and do not mean for CSS

They do not

  • prove that CSS, SATA-CODA™, ZENOASIS™, or ZEN-TECH™ improves clinical outcomes;
  • authorize CSS to diagnose, treat, manage crisis care, or make clinical decisions;
  • mean that a federal agency has endorsed the Human Layer, Cognitive State Design™, or any CSS product.

They do

make several design questions increasingly visible: orientation, continuity, human agency, environment, evidence boundaries, privacy, and human accountability.

The appropriate path is:

research → define the human-experience problem → work with qualified operators → test a bounded experience → measure what actually happens → claim only what the evidence supports

From research to working experience

ZENOASIS™ exists as the research, public-education, assessment-context, and evidence-governance layer of Cognitive State Systems™.

ZEN-TECH™ is the controlled test-and-deployment pathway.

The separation is intentional. Research can inform design without certifying a product. A working experience can generate product and operational evidence without being presented as clinical proof. Commercial interest can validate a need without establishing scientific efficacy.

Those evidence classes should remain distinct.

Where does the human experience become fragmented, unclear, passive, or difficult to continue — and is that a problem worth testing?

That is the conversation the Human Layer is designed to open.

Read the idea. Then challenge what should be proved.

The Human Layer — Designing Human Agency in the Age of Intelligent Systems by Gil Cohen is now available.

Keep the boundaries visible.

This article is educational and analytical. It does not provide medical diagnosis, treatment, psychotherapy, crisis intervention, or clinical guidance. Clinical decisions and treatment remain with qualified providers.

Cognitive State Systems LLC develops evidence-governed human-experience systems designed around orientation, continuity, reflection, accessibility, participant control, and human agency. Research informs design; it does not certify CSS products. Product evidence, operational evidence, commercial evidence, and scientific evidence are treated as distinct categories.

If you or someone you know is in crisis in the United States, call or text 988 or use the 988 Lifeline chat service.

Primary-source record

  1. U.S. Department of Health and Human Services — HHS Awards More Than $380 Million to Strengthen America’s Behavioral Health System on 988 Day ↗
  2. SAMHSA — 988 Suicide and Crisis Lifeline Crisis Center Follow-Up Programs ↗
  3. FDA — Psychedelic Drugs: Considerations for Clinical Investigations ↗
  4. FDA — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing ↗
  5. Federal Register — Public Hearing; Request for Comments ↗